Scientific advice also received from EMA on proposed PML pivotal study protocol
Paris, July 10, 2012 –
Cytheris
SA, a privately held clinical-stage biopharmaceutical company focused on
treating lymphopenia driven diseases, announces today that the European
Commission has granted an orphan designation for Cytheris’ CYT017, glycosylated
recombinant human interleukin-7 (glycosylated r-h-IL7), for the treatment of
Progressive Multifocal eukoencephalopathy (PML). Additionally, Cytheris
obtained scientific advice for a phase
IIb study protocol with CYT107 in HIV-related PML. Cytheris has reached an
agreement with the EMA on the key study endpoints. Cytheris will start this
phase IIb study, intended to be pivotal, in early 2013. PML is a severe
demyelinating disease of the central nervous system caused by the JC virus.
SA, a privately held clinical-stage biopharmaceutical company focused on
treating lymphopenia driven diseases, announces today that the European
Commission has granted an orphan designation for Cytheris’ CYT017, glycosylated
recombinant human interleukin-7 (glycosylated r-h-IL7), for the treatment of
Progressive Multifocal eukoencephalopathy (PML). Additionally, Cytheris
obtained scientific advice for a phase
IIb study protocol with CYT107 in HIV-related PML. Cytheris has reached an
agreement with the EMA on the key study endpoints. Cytheris will start this
phase IIb study, intended to be pivotal, in early 2013. PML is a severe
demyelinating disease of the central nervous system caused by the JC virus.
Read more:
Note: Although it is always exciting to read about topics like this, it is going into phase 2 trials so is several years away. It would be amazing if it did work for pml.
MSVN Medical Advisory Panel
..
Please note that all comments are moderated.
So that you can be kept up to date with MS news
Click here to: REGISTER – for our weekly e-Newsletter
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
